Please login to the form below
fasinumab
This page shows the latest fasinumab news and features for those working in and with pharma, biotech and healthcare.
Lilly, Pfizer say NGF drug works in back pain too
Pfizer/Lilly’s tanezumab – along with Regeneron/Teva’s fasinumab which reported positive phase 3 results in osteoarthritis last year – are the only NGF-targeting drugs that remain in late-stage
Latest news
-
FDA awards another non-opioid pain drug breakthrough status
Other non-opioid treatments in the late-stage pipeline are Pfizer and Lilly’s tanezumab and Regeneron and Teva’s fasinumab..
-
Regeneron and Teva close gap on rivals with NGF pain drug
Fasinumab was associated with less pain and improved functional ability compared to placebo. ... Regeneron and Teva’s nerve growth factor (NGF) inhibitor fasinumab hit the mark in a phase III osteoarthritis trial, potentially setting up a race to the
-
Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
Among numerous rivals, Regeneron was forced to halted high dose treatment of its contender fasinumab following a risk-benefit assessment conducted by an Independent Data Monitoring Committee.
-
FDA fast-tracks Pfizer and Lilly's tanezumab
a setback last October when their candidate fasinumab was placed under a clinical hold by the FDA, prompted by a case of joint destruction in its phase IIb trial.
-
FDA halts study of Teva and Regeneron's pain drug fasinumab
The FDA placed a clinical hold on a phase IIb trial of Teva and Regeneron's nerve growth factor (NGF) inhibitor fasinumab in chronic lower back pain on safety concerns. ... The decision by the US regulator followed the discovery that one patient in the
More from news
Approximately 4 fully matching, plus 7 partially matching documents found.
Latest Intelligence
-
Deal Watch September 2016
4, 325. Regeneron / Teva. Licence. Fasinumab in P3 for osteoarthritis pain, upfront payment $250m [excludes rights to Japan, Korea and other Asian markets].
-
Deal Watch October 2015
Collaboration, option to license. 339. Regeneron Pharmaceuticals/ Mitsubishi Tanabe Pharma. Fasinumab (REGN475), nerve growth factor mAb for musculoskeletal pain (p2b).
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
- HCP ENGAGEMENT STUDY: Pharma shifts top priority to HCP insights and impact metrics
- AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer
- BMS shares positive phase 3 results for Opdivo/Yervoy combination in colorectal cancer
- Stanford Medicine researchers find blood tests help predict organ failure
- GSK and GCOA report reveals global inequities in adult immunisation uptake
- A “Leaky Pipeline” and the Loss of Talented Female Physicians
No results were found
PMHub
JPA Health
JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...
Latest intelligence
- Clinical Trials Investigator and Patient Engagement Planning: A Customer Story
- ...
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
